If you have been observing market sentiment recently, you will notice a phenomenon: many projects rely on hype and trending narratives, while each rise of Injective is almost always driven by real-world events. It does not take off based on sentiment, but rather is lifted by structural forces.
The most obvious example is the New York-listed company Pineapple Financial raising $100 million to directly purchase INJ in the public market. This is not speculation; it means traditional institutions are treating INJ as a long-term asset reserve. If the previous cycle was about crypto chasing Wall Street, this cycle is about Wall Street actively pursuing on-chain finance, with Injective becoming the entry point.
Meanwhile, Injective's ETF is about to be launched in the United States, making INJ a target that can be purchased by ordinary investors and institutions in the formal market. An asset being traded both on-chain and on Wall Street means that its value will be priced by both worlds.
The actions on the technical side are equally critical. The native EVM launched by Injective not only allows Ethereum developers to migrate seamlessly but also opens up the MultiVM era. Over 40 dApps and infrastructure projects are ready to enter, which means that Injective's ecosystem scale is entering an accelerated phase.
The most transformative is that Injective is pushing RWA on-chain. It has brought traditional assets like Nvidia stocks, government bonds, gold, and foreign exchange onto the chain, allowing DeFi to directly touch real financial assets for the first time. While other public chains are still discussing concepts, Injective has already enabled asset flow on-chain.
When a project simultaneously gains capital endorsement, compliance channels, technological breakthroughs, and asset expansion, it is no longer just a public chain, but the embryonic form of financial infrastructure.
The above content is just a personal analysis and does not constitute any investment advice.
